- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:alzheimers_dementia [10.25.2017] – [Role of the Vitamin D Receptor] added section 'Other immune suppression' sallieq | home:diseases:alzheimers_dementia [02.11.2019] – [Evidence of infectious cause] sallieq | ||
|---|---|---|---|
| Line 21: | Line 21: | ||
| We are excited that someone [the team of Harvard researchers who first identified amyloid beta as an antimicrobial petide] is thinking out of the box in ways that others haven' | We are excited that someone [the team of Harvard researchers who first identified amyloid beta as an antimicrobial petide] is thinking out of the box in ways that others haven' | ||
| - | //**Brian Balin, PhD**, [[http:// | + | //**Brian Balin, PhD**, [[http:// |
| </ | </ | ||
| Line 51: | Line 51: | ||
| The similarities between Abeta [amyloid beta] and antimicrobials had been staring us in the face for decades. Abeta looks in size, structure, and biochemical properties like an antimicrobial peptide [called LL-37]. In fact, we have shown that it is a bonafide antimicrobial peptide. | The similarities between Abeta [amyloid beta] and antimicrobials had been staring us in the face for decades. Abeta looks in size, structure, and biochemical properties like an antimicrobial peptide [called LL-37]. In fact, we have shown that it is a bonafide antimicrobial peptide. | ||
| - | //**Rudolph E. Tanzi, PhD**, [[http:// | + | //**Rudolph E. Tanzi, PhD**, [[http:// |
| </ | </ | ||
home/diseases/alzheimers_dementia.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.